PRMT3: A Potential Drug Target and Biomarker (G10196)

Target Name: PRMT3

NCBI ID: G10196

PRMT3

Other Name(s): Protein arginine N-methyltransferase 3 | protein arginine methyltransferase 3 | Heterogeneous nuclear ribonucleoprotein methyltransferase-like 3 | PRMT3 variant 1 | HRMT1L3 | Protein arginine N-methyltransferase 3 (isoform 1) | ANM3_HUMAN | Protein arginine methyltransferase 3, transcript variant 1 | HMT1 hnRNP methyltransferase-like 3 | Protein arginine methyltransferase 3 | Heterogeneous nuclear ribonucleoprotein methyltransferase-like protein 3 | heterogeneous nuclear ribonucleoprotein methyltransferase-like protein 3

PRMT3: A Potential Drug Target and Biomarker

Protein arginine N-methyltransferase 3 (PRMT3) is a gene that encodes a protein involved in the post-translational modification (PTM) of proteins. Specifically, PRMT3 is involved in the N-methyation of arginine residues, which is a common modification that plays a crucial role in various cellular processes, including cell signaling, inflammation, and stress responses.

The identification of PRMT3 as a potential drug target and biomarker has significant implications for the development of new therapeutic strategies. PRMT3 has been shown to play a crucial role in the regulation of cellular processes that are often disrupted in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In cancer, PRMT3 has been shown to be involved in the regulation of cell cycle progression, apoptosis, and angiogenesis. For example, studies have shown that PRMT3 is involved in the regulation of the G1/S transition, which is a critical step in the cell cycle that determines the entry of cells into the S phase. Additionally, PRMT3 has been shown to play a role in the regulation of apoptosis, which is a critical mechanism that eliminates damaged or dysfunctional cells.

In neurodegenerative diseases, PRMT3 has been shown to be involved in the regulation of neurotransmitter synthesis and release, as well as the regulation of stress responses. For example, studies have shown that PRMT3 is involved in the synthesis and release of dopamine, which is a critical neurotransmitter that plays a role in motor control, emotion, and motivation. Additionally, PRMT3 has been shown to play a role in the regulation of stress responses, which is critical for maintaining cellular homeostasis in response to environmental stimuli.

In autoimmune disorders, PRMT3 has been shown to be involved in the regulation of immune cell function and the regulation of inflammation. For example, studies have shown that PRMT3 is involved in the regulation of T cell receptor signaling, which is critical for the development of an effective immune response to infections. Additionally, PRMT3 has been shown to play a role in the regulation of inflammation, which is critical for maintaining cellular homeostasis in the face of environmental stimuli.

In conclusion, PRMT3 is a gene that encodes a protein involved in the post-translational modification of proteins. Specifically, PRMT3 is involved in the N-methyation of arginine residues, which is a common modification that plays a crucial role in various cellular processes. The identification of PRMT3 as a potential drug target and biomarker has significant implications for the development of new therapeutic strategies for a variety of diseases. Further research is needed to fully understand the role of PRMT3 in cellular processes and to develop effective strategies for targeting this protein in the development of new therapeutic approaches.

Protein Name: Protein Arginine Methyltransferase 3

Functions: Protein-arginine N-methyltransferase that catalyzes both the monomethylation and asymmetric dimethylation of the guanidino nitrogens of arginine residues in target proteins, and therefore falls into the group of type I methyltransferases (Probable). May regulate retinoic acid synthesis and signaling by inhibiting ALDH1A1 retinal dehydrogenase activity (PubMed:33495566)

The "PRMT3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRMT3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets